Chiesi to buy KalVista in $1.9B deal for rare disease drug
Source: BioPharma Dive - Latest News
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.